연구성과로 돌아가기
2020 연구성과별 연구자 정보 (421 / 2428)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Asselah, Jamil | Asselah, J | 2 | McGill Univ, Ctr Hlth, Montreal, PQ, Canada | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Bondarenko, Igor | Bondarenko, I | 3 | Dnipropetrovsk Med Acad, Dnipro, Ukraine | U-5156-2017 | Bondarenko, Igor | 0000-0002-7071-2471 | Bondarenko, Igor | ||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Chae, YeeSoo | Chae, Y | 4 | Kyungpook Natl Univ Hosp, Daegu, South Korea | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | DaCosta, Noshir | DaCosta, N | 5 | New York Canc & Blood Specialists, East Setauket, NY USA | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Feng, Yin-Hsun | Feng, YH | 6 | Chi Mei Med Ctr, Tainan, Taiwan | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Izarzugaza, Yann | Izarzugaza, Y | 7 | Hosp Univ Fdn Jimenez Diaz, Madrid, Spain | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Lemieux, Julie | Lemieux, J | 8 | Univ Laval, CHU Quebec, Ctr Rech, Quebec City, PQ, Canada | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Liu, Mei-Ching | Liu, MC | 9 | Koo Fdn, Sun Yat Sen Canc Ctr, Taipei, Taiwan | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Marx, Gavin | Marx, G | 10 | Univ Sydney, Sydney Adventist Hosp, Syndney, NSW, Australia | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | O'Shaughnessy, Joyce | O'Shaughnessy, J | 11 | Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Oliveira, Mafalda | Oliveira, M | 12 | Hosp Univ Vall dHebron, Barcelona, Spain | I-1695-2015 | Oliveira, Mafalda | ||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Rugo, Hope | Rugo, H | 13 | Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Seidman, Andrew | Seidman, A | 14 | Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | Wright, Gail | Wright, G | 15 | Florida Canc Specialists & Res Inst, New Port Richey, FL USA | ||||||
| CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | O'Connell, Joseph | O'Connell, J | 16 | Odonate Therapeut Inc, San Diego, CA USA |
페이지 이동: